CT-95 in Advanced Cancers Associated With Mesothelin Expression

This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.

Trial Details

NCT ID
NCT06756035
Phase
PHASE1
Sponsor
Context Therapeutics Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • CT-95
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • ECOG 0 or 1
  • Subjects with evaluable disease per RECIST 1.1 or mRECIST
  • Subjects with adequate organ function.
  • Subjects with advanced cancers associated with mesothelin expression

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →